It was further noted that this median survival time exceeded those typically reported for those patients receiving amputation plus chemotherapy. The ELIAS cancer immunotherapy (ECI®) is a groundbreaking therapy that empowers the patient’s immune system, combined with an infusion of customized, blood-derived T cells that have been functionally empowered and numerically expanded to recognize and destroy cancer cells, to kill cancer cells.Įarly studies show promise: “Median Survival Time for dogs participating in the ECI-OSA-1 osteosarcoma trial was 415 days. The immune system is, perhaps, our best tool to cure some forms of cancer. Our goal is to bring viable treatment options to the pet market, so animals can benefit as well as humans. At ELIAS, we collaborate with our peers in human health to apply the advancements in immunotherapy to animals. Millions and millions of dollars fund human cancer research and treatment, but our pets traditionally haven’t benefited from it the same way that people have. Our goal was to find an alternative way to treat canine cancer, one that is effective and less taxing on our canine counterparts. Chemo kills cancer cells but because it’s so powerful, it damages surrounding healthy cells and ravages the body. Until recently, it was often the only option available. We founded ELIAS Animal Health to transform cancer treatment for pets by bring the state-of-the-art therapeutics benefiting humans into the animal world.Ĭhemotherapy has been the standard of care treatment for dogs with cancer for decades. Needs spark ideas, ideas spark innovation, and innovation births new companies.
0 Comments
Leave a Reply. |